In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
Daniela CriscuoloWriting – Original Draft Preparation
;Rosaria CatalanoProject Administration
;Carmela BavielloData Curation
;Francesco MorraMembro del Collaboration Group
;Maria MarottaMembro del Collaboration Group
;Angela Celetti
Conceptualization
2026
Abstract
In ovarian cancer, inactivation of the CCDC6 protein signals a defect in DNA repair, known as HRD. This finding might expand the pool of patients, including those who are BRCA WT, who can receive PARP inhibitors, significantly broadening access to this targeted, life-extending therapy.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
